Status:
COMPLETED
Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34
Lead Sponsor:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Conditions:
Hypoparathyroidism
Eligibility:
All Genders
17-69 years
Phase:
PHASE2
Brief Summary
This study has been important in establishing synthetic human parathyroid hormone 1-34 (PTH) as a beneficial treatment for hypoparathyroidism, superior to conventional therapy with calcium and calcitr...
Detailed Description
Vitamin D and its analogs, the conventional treatment for hypoparathyroidism, are associated with chronic hypercalciuria due to their lack of calcium-retaining effect in the kidney. This side effect u...
Eligibility Criteria
- INCLUSION CRITERIA:
This study will include patients (ages 17-69) with biochemically confirmed hypoparathyroidism.
EXCLUSION CRITERIA
Women who are pregnant will be excluded.
Key Trial Info
Start Date :
October 1 1991
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00001304
Start Date
October 1 1991
End Date
April 1 2014
Last Update
December 15 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892